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WHEN GOOD INFORMATION TRULY MATTERS:
PUBLIC SECTOR DECISION MAKERS ACQUIRING AND
USING RESEARCH TO INFORM THEIR DECISIONS
Mark Gibson∗
INTRODUCTION
Since our nation’s inception, there have been a variety of
debates about the proper boundaries between the several branches
of U.S. federal and state governments. The argument at the heart of
these debates centers on how best to advance the public interest.
While each branch operates under a different set of powers,
restraints, and processes, if this dedication to the public interest is
internalized into the deliberations of judges, legislators, and
bureaucrats, then the quality of the information these branch
officials use to inform their decisions is crucial to determining how
well the public is served.
In the past, officials of the three branches typically depended
on others to provide them with the bulk of the information
necessary to complete their work. Legislators would receive
information from lobbyists, advocates, legislative colleagues, and
constituents. Executive branch officials heard from the same
sources during policy formation, and because of their role in
program administration, heard a great deal from vendors hoping to
sell goods and services to the government as part of policy
implementation. Judges heard from the parties arguing cases
before them and in some cases, “friends of the court.” This
dependency has traditionally relied on the process of advocacy,
where both sides present their arguments to the official and the
official as decision maker determines the relative merits of the
∗

Deputy Director, Center for Evidence-based Policy.
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arguments in order to serve the public interest. Unfortunately, in
this model there is no guarantee that the information presented to
these officials by the respective advocates is of good quality. It is
conceivable that both sides, in their push to prevail, will present
only the information that is most supportive of their preferred
policy or helpful to their case and most damaging to their
opponents’, without providing a clear view of the quality or
thoroughness of the information used. In policy formation and
implementation, this problem often manifests itself through
advocates emphasizing emotional examples that may not be
representative of the broader implications of an issue or through
vendors claiming to have a study that shows that their product is
superior while conveniently forgetting to mention multiple other
studies that do not. Furthermore, judges are accustomed to having
the parties before them provide information selected not for its
thoroughness or factual strength but for its ability to support their
case.
This paper explores a trend among public officials to become
more active in gathering the information they use to inform their
decisions. It is a trend in which executive branch officials seek and
increasingly commission independent research to balance the
marketing information supplied by vendors of goods and services,
be they road contractors or cardiologists. This is a trend that finds
legislators funding nonpartisan research and participating in
networking and training to enhance their ability to access and
interpret relevant high quality information; a trend in which
members of the judicial branch appoint their own experts to
provide information on highly technical subjects, and attend
training on how to better assimilate scientific information into their
decision making; a trend that is greatly enhancing the ability of
officials throughout all branches of government to make informed
policy decisions.
This paper is based on the author’s personal experience as
senior staff in legislative leadership, a governor’s office, and as
deputy director of the Center for Evidenced-based Policy, an
academic center dedicated to linking high quality research to the
practice of policy making. Part I introduces a research process
known as a “systematic review” that is widely seen as the gold
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standard of clinical research. Part II explores the Drug
Effectiveness Review Project (DERP) as an example of using
systematic reviews to support public policy decisions. DERP is a
collaboration of fifteen states and two other organizations that
commissions and uses systematic reviews of global research to
inform drug purchasing decisions in their Medicaid, corrections,
workers’ compensation, general healthcare, and employee benefits
programs. Finally, the paper sets out examples of the criticisms
being leveled at DERP and responses to those criticisms in order to
give public officials a sense of the tone and substance of the debate
that DERP has engendered.
I. SYSTEMATIC REVIEWS AS A DECISION MAKING TOOL FOR PUBLIC
OFFICIALS
By their nature, public policy makers and the courts deal with
very serious questions. It is understandable that those who work in
these fields would covet information that would make their
decisions unerringly correct. While the science available for
supporting decisions in health policy has improved substantially,
these improvements do not signal the approach of a time when
definitive information is available to settle every question. The
improvements have not created a “silver bullet” for each vexing
issue but rather a useful tool that in some cases provides clear
direction or aids in simply ruling out unhelpful courses. It
behooves anyone involved in health policy issues to understand
how to access and evaluate the specific information available for
any given question.
One of the greatest advances in making research more useful to
policy makers is the growing production and use of systematic
reviews (SR) and, when appropriate, the meta-analysis of clinical
evidence in healthcare. A well prepared SR allows one to have far
greater confidence that the level of global knowledge on a given
set of questions is accurately represented.1 This is because the SR
1

DRUG EFFECTIVENESS REVIEW PROJECT Home
Page, at
http://www.ohsu.edu/drugeffectiveness/methods/index.htm [hereinafter DERP].
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conscientiously searches for all available relevant evidence,
rigorously analyzes its quality, and then synthesizes the best
evidence in a manner that communicates the sum of that
knowledge.
Of course, any public official worthy of the title hopes for
research that provides “road to Damascus” clarity on the issue of
the moment. While this is possible, it is more likely that the
assistance provided even by a SR will be more nuanced. Often,
officials must settle for the “best available” evidence at the time,
which may include gaps and inconsistencies. Even less directly
helpful can be the knowledge that there is no good evidence
available to address a given issue. However, even this modest
knowledge can be useful. Considering that in public policy, a
failure to make a decision constitutes a decision to maintain the
status quo, understanding the best available evidence can help a
public sector decision maker judge the relative risk of selecting
between the status quo and a possible initiative. For policy makers,
judges, and jurors, understanding that there is no good evidence
can provide a key counter to the claims of advocates expressing
certainty in the merit of their position, product, or client.
II. DRUG EFFECTIVENESS REVIEW PROJECT: POLICY MAKERS
DIRECTLY ACQUIRING AND USING RESEARCH
On average, healthcare and education are the two largest
expenditures in state budgets. Among the states, Medicaid
expenditures now exceed expenditures on primary and secondary
education.2 One of the fastest growing segments of Medicaid
spending is for prescription drugs. States are working diligently to
ensure that they receive value for the dollars they spend. One
strategy includes promulgating preferred drug lists, a process in
which the state creates incentives for patients to use drugs that are
similar in effectiveness but lower in cost. The key to successfully
using a preferred drug list is making sure that the preferred drug is
2

NATIONAL GOVERNOR’S ASSOCIATION AND NATIONAL ASSOCIATION OF
STATE BUDGET OFFICERS, THE FISCAL SURVEY OF THE STATES: JULY 2005 4,
(June 2005) available at http://www.nasbo.org/Publications/fiscalsurvey/
fsspring2005.pdf.
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of equal or greater effectiveness than other drugs used to treat a
given condition. To ensure that they have the best possible
information on which to base their selection of preferred drugs,
fifteen states (and two other organizations) have formed an
international collaboration called the Drug Effectiveness Review
Project (DERP).
DERP provides systematic evidence-based reviews of the
comparative efficacy/effectiveness and safety of drugs in twentysix of the most commonly prescribed drug classes. The project is
funded by multiple public and private entities, including fifteen
states, the California Healthcare Foundation, and the Canadian
Coordinating Office for Health Technology Assessment. In
governing the project, these participating entities determine and
prioritize the classes to be reviewed and the content of the research
questions. When a systematic review is completed, each member
organization makes its own decision on whether and how the
results will inform the policies for which it is responsible.
The project is administered by the Center for Evidence-based
Policy (CEP) at Oregon Health & Science University (OHSU).3
The CEP supports the project’s governance, contracting, and
communications processes.
The reports are produced by a consortium of Evidence-based
Practice Centers (EPCs), which are research organizations that are
competitively selected by the federal Agency for Healthcare
Research and Quality (AHRQ).4 The research process is
coordinated by the Oregon EPC at OHSU. The Oregon EPC is
independent and separate from the CEP at OHSU.5

3

OREGON
HEALTH
AND
SCIENCE
UNIVERSITY,
http://www.ohsu.edu/policycenter (last visited Dec. 2005). Details regarding
DERP, including current drug class reports, are available to the public at the
project website http://www.ohsu.edu/drugeffectiveness.
4
EVIDENCE-BASED PRACTICE CENTERS, http://www.ahrq.gov/clinic/epc
(last visited Dec. 2005). Other than commissioning research with these Centers,
DERP has no relationship with AHRQ.
5
DERP, supra note 1.
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A. DERP Process

The entire DERP process is fully transparent and patterned
after the systematic review process followed by AHRQ. Public
input is solicited and considered multiple times for each report. All
sources of information are fully disclosed, and investigators are
prohibited from having any economic interests in the subjects they
study.
The DERP process begins with the creation of a set of research
questions. These key questions are formed through an iterative
process in which interested parties exchange feedback in public
meetings held in participating states and researchers and policy
makers consult with one another directly in order to create a first
draft. This draft is then posted on the project web site and
comments are solicited from the industry and the public at large.
Once public comment has been received and considered, the policy
makers representing the organizations participating in the project
agree on the final form of the key questions. Because the questions
define the scope and focus of the report, the drugs in the class,
populations of interest, diseases affected by the drugs, outcomes of
interest, and the most appropriate types of studies to be included in
the report, creating these questions can take several months.
When the key questions are finalized, they are sent to each
pharmaceutical manufacturer in the United States and Canada
along with a request for any research evidence the manufacturer is
willing to share that is relevant to the questions. Informational
dossiers submitted by the drug companies in response to this
request are forwarded to the researchers for their consideration as
they compile the report. Five to ten percent of the citations in a
typical evidence report come as a result of these submissions.6
Dossiers submitted by the companies are available to the public
upon request.
As dossiers are gathered, the researchers begin their own
search for clinical evidence. They routinely search the major
clinical data bases such as EMBASE, MedLINE, and the Cochrane

6

Estimate provided by John Santa, MD, MPH, Medical Director for DERP.
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Registries of Clinical Trials and Systematic Reviews.7 In addition,
the bibliographies of studies considered relevant are also searched
for citations not found through the electronic databases.
Studies identified as potentially useful are then read in detail to
determine if they are relevant to the key questions. If they are
found to be relevant, the design and execution of the study is
carefully evaluated and those studies with flawed methodology are
then removed from consideration. Evaluating the quality of the
relevant research is a critical step because much of the research
available to compare similar drugs is of poor quality. Even
randomized controlled trials, regarded as the gold standard of
clinical research, can be poorly designed, executed, or reported in
ways that leave consumers and decision makers with a misleading
view of reality. Common shortcomings in the research and the
reporting of such research are succinctly catalogued by David
Sackett and Andrew Oxman and include but are not limited to:
• run in periods where only patients previously
determined to tolerate the drug are included in the trial
thereby underestimating the adverse events associated
with the drug in the trial;
• high dose/low dose comparisons where the drug of the
company sponsoring the study is administered at a high
dose while a competitor’s drug is administered at a low
dose thus increasing the chance that the high dose drug
will show a greater response;
• multiple study analyses (meta-analyses) that include
only studies that show a favorable result and
eliminating studies that show indeterminate or
unfavorable findings;
• when the overall research is indeterminate, the
performance of subgroup analyses until favorable
results can be found then report only the favorable
results and ignore the rest.8
7

G. Gartlehner et al., Drug Class Review on Second Generation
Antidepressants 9, 9-10 (2006), at http://www.ohsu.edu/drugeffectiveness/
reports/documents/Antidepressants%20Final%20Report%20Update%202.pdf.
8
David L. Sackett & Andrew D. Oxman, HARLOT plc: An Amalgamation
of the World’s Two Oldest Professions, 327 BRITISH MEDICAL JOURNAL 1442,
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After carefully analyzing studies that are potentially useful,
studies found to be of good quality are then synthesized into a draft
report which is both posted for public comment on the project’s
web site and sent out to peer reviewers who have experience in
both evaluating evidence and with the subject area addressed by
the drug class under review. Once received, the public and peer
review comments are considered in detail. Legitimate concerns
raised by either the public or the peer reviewers that fit the scope
of the report are addressed in the final draft, which is posted on the
project website in the public domain.9
DERP does not consider the cost of the drugs in its reports nor
does it recommend a preferred drug in a class. The manner in
which a report is used (or not used) is entirely up to the
participating organization and the policies in their jurisdictions.
These uses range from creating prescriber education materials
based on the reports, to evaluating the clinical advice given by a
pharmacy benefits manager, to being the primary source of clinical
information for a preferred drug list pharmacy and therapeutics
committee. States that use the reports to inform their pharmacy and
therapeutics committees have open public meetings for decision
making, and provide opportunities for public testimony on the
policies under consideration.10
Completed reports are eventually updated as new drugs, new
evidence, and new issues are identified and assessed in the context
of previous evidence. For example, the Statin drug class report has
been updated four times since the original report was completed in
2002. The report for atypical antipsychotic medication is currently
being updated in order to assess the importance of observational
trials and a recent large comparative trial.
The experience of public decision makers in the
DERP project is illustrative of some of the advantages,
disadvantages, and challenges such an approach brings. One of the
greatest advantages of using systematic reviews in this way is that
1442-1445
(2003),
available
at
http://www.urmc.rochester.edu/
smd/student/defib/pdf/BMJ_Harlot.pdf.
9
DERP, supra note 1.
10
Information on the decision making bodies of each state participating in
DERP are available on the Project website. Id.
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decision makers have better information at their disposal on the
comparative effectiveness and safety of the medications they are
buying than other purchasers or even their suppliers. This allows
them to have confidence that the drugs they select are high quality
and that the savings they achieve by preferring one drug over
another do not compromise the quality of the healthcare delivered
to their patients.
The process of creating a systematic review can pose many
challenges. First, it can take a significant amount of time to
complete. While most states would prefer to receive the
information on drug classes in the space of just a few months in
order to make decisions more quickly, on average, these
comparative drug class studies take between eight and ten months
to complete. Overall, the DERP project has taken approximately
three years to complete twenty-five original reviews. Moreover,
systematic reviews must also be updated on a regular basis.
Depending on the amount of research underway in a given class,
this may need to be done annually and in some cases even more
frequently.
In addition to being time consuming, systematic reviews can
also be expensive. For instance, the first casses reviewed by DERP
averaged $110,000 per report. Also, in their completed form, SRs
are highly technical documents, making translation for use in the
policy process laborious as well. However, these challenges can be
overcome through planning, patience, expense sharing among
interested parties, and careful summation of the studies that allow
officials and the public to accurately understand the essence of the
research.
Unfortunately, as one might expect, those threatened by the use
of this research have attempted to discredit the research or limit its
use. These efforts have run a continuum from blatant
misrepresentation to reasonable questions of methodology that will
require ongoing deliberation within the research and policy
communities. The DERP experience can give public officials a
sense of the tone and substance of the debate they will experience
even when they are using what is demonstrably the best available
information to inform their work.
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B. Critisim of DERP Reports

The use of DERP reports raises several important concerns.
However, when judging DERP’s approach, or any other attempt to
use systematic reviews to inform public decisions, it is important
to compare it to the other information development and
dissemination strategies currently used in government and
industry. Recognizing this context is important because new
initiatives are often judged in comparison to a hypothetical ideal
rather than against the current approaches they seek to change.
This allows defenders of the status quo to argue against
constructive change without explicitly defending the status quo.
Thus, critics will profess support for evidence based medicine
while they belittle DERP because its reports do not take into
account the infinite variability of individuals. Of course, no study
using existing technology could ever provide that level of detail, so
the fact that DERP is a marked improvement over what is currently
available to help policy makers, consumers, and providers decide
which drugs are better overall is denigrated because it does not
provide perfect information for every patient.11 The common
criticisms of DERP and their implications for other public sector
decision makers using similar research to inform their decisions
are addressed in detail below.
1. DERP Conflicts with the Principles of Evidence-Based Medicine
The criticism that DERP conflicts with the principles of
evidence-based medicine almost always relies on selective
reference to Dr. David Sackett, an international authority on
evidence-based medicine. Critics cite Dr. Sackett’s article from
1996 as support for their claim that all forms of information,
including observational studies and patient preference, should be
used in DERP’s assessment of the efficacy or effectiveness of the
drugs it studies.12 These criticisms ignore that in that same article,
11

MENTAL HEALTH ASSOCIATION IN CALIFORNIA, Background,
http://www.mhac.org/advocacy/alliance_background.cfm.
12
David L. Sackett et al., Evidence Based Medicine: What It Is and What It
Isn’t, 312 BRITISH MEDICAL JOURNAL 71, 71-72 (1996).
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Sackett went on to say:
It is when asking questions about therapy that we should try
to avoid the non-experimental approaches, since these
routinely lead to false-positive conclusions about efficacy.
Because the randomized trial, and especially the systematic
review of several randomized trials, is so much more likely
to inform us and so much less likely to mislead us, it has
become the gold standard for judging whether a treatment
does more good than harm.13
The systematic review of all available randomized controlled
trials (RCTs) called for by Sackett is exactly what DERP provides.
This is in sharp contrast to the kind of information generally used
as the basis for establishing comparative efficacy in the industry.
There is no evidence that pharmaceutical companies conduct
systematic comparative reviews of the drug classes. Many
purchasers rely on cost effectiveness analyses that begin with a
bare minimum of evidence and a consultant’s opinion rather than a
synthesis of the entire relevant evidence. Additionally, most
purchasers, insurers, and pharmacy benefits managers consider the
information they rely on for their decisions to be proprietary and
therefore secret, even if they profess to be “evidence-based.” Thus,
there is no way to judge the quality or objectivity of the
information used. It appears that DERP’s standard of evidence is
of higher quality than that of its primary critics.
More fundamentally, the question should not be whether DERP
or any information effort is consistent with anyone’s assertion of
what is or is not evidence-based medicine. Rather, the truly
important question is whether decisions to wisely purchase or
prescribe drugs are helped or hindered by properly executed
systematic reviews comparing drugs within classes. Clearly, the
appropriate use of these reviews can be of enormous help to
decision makers. This is especially true when the alternative is to
depend on a model of research and information dissemination that
has at its core the selective use of information to maximize market
share. Similarly, the practice of evidence-based medicine could be
helped substantially if the healthcare industry as a whole shared
13

Id.
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DERP’s commitment to systematically reviewing all high quality
evidence, and to public participation and full disclosure of all
research results.
2. DERP is Not Sufficiently Transparent and Inclusive
The critical elements of the DERP processkey questions,
research considered, industry dossiers, public comments, draft
reports, final reports, local decision making processesare
transparent and inclusive: they are either posted on the DERP
website or available on request.14 The current participants in DERP
all have public processes in which the DERP reports are available
or presented in public.
Again, the DERP process compares favorably to that used
generally by healthcare purchasers, providers, and manufacturers.
In fact, the overall information available to practitioners and
consumers could be improved substantially if similar standards of
transparency and inclusiveness were adopted by drug and device
manufacturers, pharmacy benefits managers, insurers, and the
creators of practice guidelines.
3. DERP Defines Evidence Too Narrowly
This criticism seeks to discredit DERP because of its emphasis
on randomized controlled trials (RCTs) in determining
comparative efficacy/effectiveness.15 However, making the breadth
of the evidence the primary indicator of its quality is a mistake. A
more useful approach is to determine whether the evidence in
question is appropriate for the use to which it is put.
DERP relies primarily on RCTs to determine the
efficacy/effectiveness of medications under review because, as
Sackett stated, they are much less likely to mislead us than other
forms of research that are less rigorous in their efforts to eliminate
14

DERP
Methods,
http://www.ohsu.edu/drugeffectiveness/methods/
index.htm.
15
ISPOR HEALTH SCIENCE POLICY COUNCIL, WHERE DOES OUTCOMES
RESEARCH FIT INTO EVIDENCE-BASED HEALTHCARE DECISION-MAKING?,
available at http://www.ispor.org/councils/Decision_making.asp.
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bias and confounding factors from their work. To minimize the
potential for bias, RCTs require random assignment of study
participants to either the group receiving the experimental
intervention (active) or the group not receiving the experimental
intervention (control). Those who evaluate the effects of the
intervention must be blind to whether the subject was in the active
or control arm of the study. Well-prepared RCTs are almost always
conducted in highly controlled settings with carefully selected
participants who have similar characteristics in order to make sure
the methodology is carefully carried out, and to attempt to make
certain that changes observed are actually due to the treatment and
not to chance, subconscious decisions made by researchers, or an
underlying characteristic of the subject. The highly controlled
nature of these trials is very effective at removing bias from the
study, but legitimate questions remain about how readily they can
be generalized to a community care setting in much more
complicated patients.
To address some of these concerns, researchers are developing
large scale community based trials that still have randomization
and blinding in their procedures, but reflect more closely the
results one could expect in the real world. DERP recognizes that
well-prepared large scale practical controlled trials comparing the
effectiveness of these drugs in community practice settings can be
better than RCTs done in a research setting, and we use them
whenever they are available.16 Unfortunately, such effectiveness
studies are rare and the fact that our inclusive search strategy finds
so few of them highlights a flaw in the priority setting among the
major funders of comparative drug research.
In addition, while DERP gives preference to well done RCTs
when assessing efficacy/effectiveness, it also routinely considers
observational studies when evaluating adverse events because
these studies often include larger populations and are of longer
duration than RCTs. This addresses the problem posed by the fact
that RCTs are often too short and the sample size too small to find
16

Sean R. Tunis et al., Practical Clinical Trials: Increasing the Value of
Clinical Research for Decision Making in Clinical and Health Policy, 290
JAMA 1624, 1624-32 (2003).
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adverse events associated with longer term and broader use. This is
especially important given the number of medications now
designed to be taken for the remainder of a patient’s life.
These issues of breadth versus quality of evidence will
continue to be a focus of intense discussion because at present
there is no consensus among clinicians, researchers, or decisionmakers about the validity of observational studies for assessing the
comparative effectiveness of different drugs. The most common
comparative observational studies—retrospective designs such as
the case-control study, and prospective designs such as cohort
studies—were designed to test hypotheses about causal agents in
the epidemiology of disease. Their suitability for drawing valid
conclusions about comparative efficacy or effectiveness in clinical
practice has not yet been established.
To advance this discussion, DERP is testing whether
observational studies are useful in determining efficacy or
effectiveness by investing resources to evaluate the quality of
evidence generated by observational studies of atypical antipsychotic medications, ADHD medications, targeted immune
modulators, and inhaled corticosteroids. This effort, along with
initiatives underway by AHRQ related to the Medicare
Modernization Act,17 should shed additional light on whether they
are useful and if so, what methods are essential to that utility.
Even given this ongoing debate, the DERP approach appears to
compare favorably to the common practice of using narrow
placebo controlled efficacy trials as the basis for direct-toconsumer and physician-focused advertising campaigns. It is also
clearly superior to the practice of manipulating evidence related to
a product by suppressing research that does not support the desired
point of view or by only releasing partial results from major
studies.18 The willingness of the DERP project to use its limited
resources in a good faith effort to analyze the appropriate use of
17

Medicare Prescription Drug, Improvement, and Modernization Act of
2003, Pub. L. No. 108-173, 117 Stat. 2066 (2003). See also
http://www.effectivehealthcare.ahrq.gov/aboutUs/aboutUs.cfm#MMA.
18
P. Juni et al, Are Selective COX 2 Inhibitors Superior to Traditional Non
Steroidal Anti-inflammatory Drugs, 324 BRITISH MEDICAL JOURNAL 1287,
1287-1288 (2002).
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observational studies and to disclose those results publicly speaks
to the project’s commitment to the public interest.
4. DERP Findings Do Not Sufficiently Address Variations Among
Subpopulations19
In every DERP review, one of the key questions always
focuses on what the evidence shows about any differential impact
of a medication on a given subpopulation, and whether that
population is defined by gender, race, age or ethnicity. DERP
reports only reach conclusions regarding subpopulations that are
supported by the evidence. Unfortunately DERP’s research has
found that there is a real shortage of good quality studies of
subpopulations. This lack of information is largely the result of the
decisions made by the funders of primary research, rather than
DERP.
Nonetheless, this raises the question of whether DERP
participants should limit the use of evidence from RCTs if studies
do not focus specifically on a given subpopulation and should
instead consider less rigorously designed studies, if available, on
that subpopulation. Those who advocate for this position would
seem to argue for adopting a lower standard of evidence for such
groups by ignoring high quality information developed in other
groups until more rigorous studies of the precise group in question
can be completed. Additional study and discussion should be
undertaken within the research and policy communities to
determine if the public interest is better served if the treatment for
subpopulations is based on lower quality studies that include them
rather than high quality studies that look at a general population.
Few dispute, however, that the major funders of research
(including the pharmaceutical industry) should design and fund
more high quality studies that directly consider the effects of
treatments on subpopulations.
5. DERP Confuses the Absence of Evidence for Evidence of No
19

AGENCY FOR HEALTHCARE RESEARCH AND QUALITY Info Page,
http//www.mhac.org/advocacy/alliance_background.cfm.
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Difference Among Drugs

A careful reading of all of the DERP reports will show that
DERP never claims that the lack of evidence of a difference should
be interpreted as evidence that there is no difference. DERP reports
specify what evidence exists and what evidence is lacking, and it is
up to the purchasers who use the reports to decide if they are
willing to pay more for medications that have no evidence of
superiority.
Concerns have been expressed that some DERP participants
make value decisions in the absence of evidence. The systematic
review of long acting narcotics used for the relief of chronic pain,
for example, shows that there are no fair or good quality
randomized controlled trials comparing these drugs to each other.
While there is no good quality evidence comparing the
effectiveness of these drugs, there are substantial price differences
among them. So, the policy question raised by this lack of
evidence coupled with a significant difference in price focuses on
what constitutes good stewardship of taxpayer dollars and whether
public payers for health services should insist on some credible
clinical evidence before paying a significantly higher price for a
comparable medication.
6. DERP is Focused Solely On Cost and Should Be Rejected
Because it May Be Misused and Do Harm to Vulnerable Persons
A classic example of this criticism is an article in The Medical
Herald.20 In its April 2005 edition, the newspaper headlined the
story “States Misuse Evidence-Based Medicine.” As reported,
several physicians and the chairman of the board at Pfizer
Pharmaceuticals roundly condemned using medical evidence in
policy formulation as a danger to vulnerable populations,
especially racial minorities. The article supports the use of
evidence in a clinical setting by a single practitioner in consultation
with a patient but alleges, for example, that “minorities will be
20
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hardest hit by faulty analysis by untrained government bureaucrats,
with many being denied life-saving drugs because they cost too
much.”21
While the article is full of numerous suggestions that using
evidence in Medicaid policy decisions, especially decisions to
control costs, will result in denial of beneficial services to
vulnerable populations, there is not one example cited that
documents this. Curiously, the authors focus their worries on
programs that are using high quality evidence, rather than those
programs that ignore evidence and use draconian measures such as
limiting the number of prescriptions Medicaid recipients receive
regardless of their condition or the effectiveness of additional
prescriptions to treat them.
The article, written without quoting one Medicaid official or
representative of DERP, seems to take the position that working to
control the cost of Medicaid is optional. It conveniently ignores the
enormous cost increases recently seen in Medicaid, the consensus
that they are unsustainable, and the role that drug expenditures
play in those increases. The article conveniently sidesteps the
question of whether it is better to use or ignore good quality
evidence when taking unavoidable steps required to control costs
in Medicaid. The parties quoted in the article seem to argue that it
is permissible to deny persons access to life saving medications by
pricing them at a level that is unaffordable to millions of
Americans while it is unconscionable for state governments to try
to use evidence to make sure that their polices are clinically sound.
CONCLUSION
Public sector decision makers in all branches of government
need consistently good information to inform the important
decisions they make. Legislators and executive branch officials
need such information in policy formation and implementation,
and the judiciary needs it to determine if the law is being followed.
Research that is directly applicable to public sector healthcare
decisions is improving and increasing in prevalence. This trend is
21

Id. at 25.
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supported by a more aggressive acquisition of good quality
research by public sector decision makers. The barriers to
increasing this acquisition even further can be reduced by a wider
recognition of its utility that increases demand for it, by
jurisdictions sharing the costs of directly commissioning research
relevant to policy, and by focusing the research on questions that
have immediate relevance to the public interest. The public interest
is well served when good quality research is used to inform public
sector decisions, and by a vigorous debate about what defines good
quality research and decision making processes for these purposes.

